PMID- 37175994
OWN - NLM
STAT- MEDLINE
DCOM- 20230515
LR  - 20230515
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 9
DP  - 2023 May 5
TI  - PRP of T2DM Patient Immobilized on PCL Nanofibers Stimulate Endothelial Cells 
      Proliferation.
LID - 10.3390/ijms24098262 [doi]
LID - 8262
AB  - Diabetic foot ulcers (DFU) are a common complication of Type 2 Diabetes Mellitus 
      (T2DM). Development of bioactive wound healing covers is an important task in 
      medicine. The use of autologous platelet-rich plasma (PRP) consisting of growth 
      factors, cytokines and components of extracellular matrix is a perspective 
      approach for DFU treatment, but we previously found that some T2DM PRP samples 
      have a toxic effect on mesenchymal stem cells (MSCs) in vitro. Here, we 
      covalently immobilized T2DM PRP proteins on polycaprolactone (PCL) nanofibers, 
      and the growth of endothelial cells on the PCL-COOH-PRP was investigated. 
      Additionally, the level of NO reflecting the cytotoxic effects of PRP, 
      angiogenin, and VEGF levels were measured in T2DM PRP samples. The results showed 
      that the application of PCL-COOH-PRP nanofibers allows to remove the cytotoxicity 
      of T2DM PRP and to improve endothelial cell adhesion and proliferative activity. 
      We showed that the origin of T2DM PRP (the level of PRP toxicity or 
      presence/absence of DFU) does not influence the efficiency of cell growth on 
      PCL-COOH-PRP, and on the level of angiogenin, vascular epidermal growth factor 
      (VEGF) in PRP itself.
FAU - Solovieva, Anastasiya O
AU  - Solovieva AO
AUID- ORCID: 0000-0002-7740-8456
AD  - Research Institute of Clinical and Experimental Lymphology-Branch of the ICG SB 
      RAS, 2 Timakova Str., 630060 Novosibirsk, Russia.
FAU - Sitnikova, Natalia A
AU  - Sitnikova NA
AUID- ORCID: 0000-0002-8226-8996
AD  - Research Institute of Clinical and Experimental Lymphology-Branch of the ICG SB 
      RAS, 2 Timakova Str., 630060 Novosibirsk, Russia.
FAU - Nimaev, Vadim V
AU  - Nimaev VV
AUID- ORCID: 0000-0002-9889-3729
AD  - Research Institute of Clinical and Experimental Lymphology-Branch of the ICG SB 
      RAS, 2 Timakova Str., 630060 Novosibirsk, Russia.
FAU - Koroleva, Elena A
AU  - Koroleva EA
AUID- ORCID: 0000-0002-8629-7030
AD  - Research Institute of Clinical and Experimental Lymphology-Branch of the ICG SB 
      RAS, 2 Timakova Str., 630060 Novosibirsk, Russia.
FAU - Manakhov, Anton M
AU  - Manakhov AM
AUID- ORCID: 0000-0003-4517-1682
AD  - Research Institute of Clinical and Experimental Lymphology-Branch of the ICG SB 
      RAS, 2 Timakova Str., 630060 Novosibirsk, Russia.
LA  - eng
GR  - 18-75-10057/Russian Science Foundation/
PT  - Journal Article
DEP - 20230505
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 62229-50-9 (Epidermal Growth Factor)
SB  - IM
MH  - Humans
MH  - Vascular Endothelial Growth Factor A/metabolism
MH  - Endothelial Cells/metabolism
MH  - *Nanofibers
MH  - *Diabetes Mellitus, Type 2
MH  - Cell Proliferation
MH  - Epidermal Growth Factor/pharmacology
MH  - *Platelet-Rich Plasma/metabolism
MH  - *Diabetic Foot/therapy
PMC - PMC10179416
OTO - NOTNLM
OT  - Type 2 Diabetes Mellitus (T2DM)
OT  - diabetic foot ulcers (DFU)
OT  - platelet-rich plasma (PRP) therapy
OT  - polycaprolactone (PCL) nanofibers
COIS- The authors declare no conflict of interest.
EDAT- 2023/05/13 15:13
MHDA- 2023/05/15 11:42
PMCR- 2023/05/05
CRDT- 2023/05/13 01:30
PHST- 2023/03/21 00:00 [received]
PHST- 2023/05/01 00:00 [revised]
PHST- 2023/05/02 00:00 [accepted]
PHST- 2023/05/15 11:42 [medline]
PHST- 2023/05/13 15:13 [pubmed]
PHST- 2023/05/13 01:30 [entrez]
PHST- 2023/05/05 00:00 [pmc-release]
AID - ijms24098262 [pii]
AID - ijms-24-08262 [pii]
AID - 10.3390/ijms24098262 [doi]
PST - epublish
SO  - Int J Mol Sci. 2023 May 5;24(9):8262. doi: 10.3390/ijms24098262.